0
Signin
countryflagUS

18889881171

AAPL 183.36 5.9701% MSFT 406.8 2.2522% GOOG 169.01 0.3265% GOOGL 167.21 0.3541% AMZN 186.235 0.8202% NVDA 887.83 3.4562% META 452.05 2.3479% TSLA 181.14 0.6277% TSM 141.56 3.9125% LLY 734.97 -2.7702% V 268.47 0.3214% AVGO 1278.11 3.1924% JPM 190.51 -0.6% UNH 492.45 -0.1055% NVO 123.05 -0.7821% WMT 59.82 0.1842% LVMUY 168.5 2.1584% XOM 116.02 -0.1893% LVMHF 841.0 1.8789% MA 443.58 0.5622%

Sunshine Biopharma Inc

Healthcare US SBFM

0.84USD
0.0025(0.30%)

Last update at 2024-05-03T20:13:00Z

Day Range

0.810.92
LowHigh

52 Week Range

0.201.30
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -26.51114M -12.43645M -2.78409M -1.07805M -2.15616M
Minority interest - - - - -
Net income -26.74444M -12.76526M -0.89768M -1.46144M -2.15616M
Selling general administrative 8.90M 1.87M 0.55M 0.62M 1.21M
Selling and marketing expenses 0.58M - - - -
Gross profit 1.70M 0.11M 0.05M 0.01M 0.06M
Reconciled depreciation 0.03M 0.01M 0.01M 0.01M 0.05M
Ebit -8.67403M -2.44013M -0.57687M -0.64164M -2.03826M
Ebitda -8.13022M -2.42739M -2.61732M -0.94261M -1.98890M
Depreciation and amortization 0.54M 0.01M -2.04045M -0.30098M 0.05M
Non operating income net other - - - - -
Operating income -8.67403M -2.44013M -0.57687M -0.64164M -1.16654M
Other operating expenses 13.02M 2.67M 0.65M 0.66M 1.61M
Interest expense 0.04M 0.33M 0.17M 0.12M 0.16M
Tax provision 0.23M 0.00000M 0.00000M 0.00000M -
Interest income 0.52M - - - -
Net interest income 0.48M -0.32882M -0.16811M -0.11590M -0.15942M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.23M 0.33M -1.88641M 0.38M -0.04153M
Total revenue 4.35M 0.23M 0.07M 0.02M 0.45M
Total operating expenses 10.37M 2.55M 0.62M 0.65M 1.22M
Cost of revenue 2.65M 0.12M 0.03M 0.01M 0.39M
Total other income expense net -17.83711M -9.99631M -2.20722M -0.43642M -0.83020M
Discontinued operations - - - -0.58224M -0.01820M
Net income from continuing ops -26.74444M -12.43645M -2.78409M -1.07805M -2.15616M
Net income applicable to common shares -26.74444M -12.43645M -2.78409M -1.66029M -2.15616M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 29.24M 2.20M 1.05M 0.10M 1.15M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.28M 0.04M 0.01M 0.00885M 0.00134M
Total liab 7.62M 1.99M 2.00M 0.83M 1.20M
Total stockholder equity 21.63M 0.21M -0.95484M -0.73538M -0.05575M
Deferred long term liab - - - - -
Other current liab 0.50M 0.05M 0.02M 0.02M 0.00929M
Common stock 0.02M 0.00259M 0.35M 0.04M 0.09M
Capital stock 0.02M 0.10M 0.45M 0.09M 0.14M
Retained earnings -59.39961M -32.65517M -20.21873M -17.43464M -15.77435M
Other liab 0.04M - - - 0.29M
Good will - - - - 0.67M
Other assets - - - - -
Cash 21.83M 2.05M 0.99M 0.04M 0.12M
Cash and equivalents - - - - -
Total current liabilities 6.93M 0.09M 1.05M 0.83M 0.91M
Current deferred revenue - - - - 0.05M
Net debt -17.55221M -0.14517M 0.92M 0.68M 0.84M
Short term debt 3.63M 1.90M 0.96M 0.72M 0.66M
Short long term debt 3.63M - 0.96M 0.72M 0.66M
Short long term debt total 4.27M 1.90M 1.91M 0.72M 0.95M
Other stockholder equity 80.84M 32.79M 18.82M 16.62M 15.59M
Property plant equipment - 0.00706M 0.02M 0.03M 0.05M
Total current assets 27.31M 2.20M 1.03M 0.07M 0.21M
Long term investments - - - - -
Net tangible assets - 0.11M -1.05484M -0.78538M -0.10575M
Short term investments - - - - -
Net receivables 1.91M 0.00780M 0.00192M 0.00043M 0.09M
Long term debt - 1.90M 0.95M - 0.29M
Inventory 3.29M 0.11M 0.02M 0.02M -
Accounts payable 2.80M 0.04M 0.06M 0.10M 0.19M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.16M -0.02314M -0.00287M -0.00249M -0.00374M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.00706M - 0.03M 0.94M
Deferred long term asset charges - - - - -
Non current assets total 1.93M 0.00706M 0.02M 0.03M 0.94M
Capital lease obligations 0.64M - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -14.61939M 0.00000M -0.00119M -0.01528M -0.01391M
Change to liabilities 0.00000M -0.01816M -0.03501M -0.01869M 0.06M
Total cashflows from investing activities -14.61939M -14.61939M -0.00119M -0.01528M -0.01391M
Net borrowings - 2.90M 1.57M 0.42M 0.50M
Total cash from financing activities 39.47M 2.90M 1.61M 0.44M 0.53M
Change to operating activities - -0.00288M 0.00172M 0.00411M 0.00840M
Net income -26.74444M -12.43645M -2.78409M -1.66029M -2.15616M
Change in cash 19.78M 1.06M 0.95M -0.07472M 0.00768M
Begin period cash flow 2.05M 0.99M 0.04M 0.12M 0.11M
End period cash flow 21.83M 2.05M 0.99M 0.04M 0.12M
Total cash from operating activities -5.24836M -1.82913M -0.65730M -0.49580M -0.51281M
Issuance of capital stock 30.37M - - - 0.00000M
Depreciation 0.03M 0.01M 0.01M 0.01M 0.05M
Other cashflows from investing activities - - - -0.01442M -0.01442M
Dividends paid - - 0.00000M 0.00000M 0.00000M
Change to inventory 0.04M -0.08188M -0.00786M -0.01591M -0.01591M
Change to account receivables -0.52449M -0.00588M -0.00149M -0.00043M -0.01545M
Sale purchase of stock -0.09900M - - - -
Other cashflows from financing activities 13.19M 3.38M 1.71M 0.50M 0.72M
Change to netincome 18.32M 10.70M 2.16M 1.18M 1.54M
Capital expenditures 0.30M 0.00000M 0.00119M 0.00086M 0.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 3.15M -0.10880M -0.04264M -0.03092M 0.05M
Stock based compensation - - - - -
Other non cash items 18.32M 10.70M 2.16M 1.18M 1.54M
Free cash flow -5.55335M -1.82913M -0.65849M -0.49666M -0.53166M

Fundamentals

  • Previous Close 0.84
  • Market Cap7.45M
  • Volume4904426
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.50920M
  • Revenue TTM20.35M
  • Revenue Per Share TTM0.85
  • Gross Profit TTM 1.70M
  • Diluted EPS TTM-1.63

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SBFM
Sunshine Biopharma Inc		 0.0025 0.30% 0.84 - - 0.32 0.30 32.47 0.45
ZTS
Zoetis Inc		 -0.16 0.10% 167.07 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.40 1.22% 32.73 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 0.23 0.14% 162.23 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.10 0.75% 13.37 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents. It also offers Essential 9, an amino acids capsules; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. Sunshine Biopharma, Inc. is based in New York, New York.

Sunshine Biopharma Inc

6500 Trans-Canada Highway, Pointe-Claire, QC, Canada, H9R 0A5

Key Executives

Name Title Year Born
Dr. Steve N. Slilaty Ph.D. Chairman, CEO & Pres 1952
Mr. Camille Sebaaly CFO & Sec. 1959
Dr. Abderrazzak Merzouki COO & Director 1964
Mr. Robert G. Ferreira Pres of Sunshine Bio Investments Inc 1962

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).